Advances in the development of new tuberculosis drugs and treatment regimens

Nature Reviews Drug Discovery

Volumn 12, Issue 5, 2013, Pages 388-404

  Zumla, Alimuddin ^a   Nahid, Payam ^b   Cole, Stewart T ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID PLUS ISONIAZID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE; UNINDEXED DRUG; VIOMYCIN;

DNA SUPERCOILING; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDEMIC DISEASE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; IMMUNOMODULATION; LATENT TUBERCULOSIS; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REVIEW; RISK FACTOR; SHORT COURSE THERAPY; TREATMENT DURATION; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG COMBINATIONS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RESEARCH DESIGN; TUBERCULOSIS;

EID: 84877267006     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4001     Document Type: Review

References (130)

1. Zumla, A., Raviglione, M., Hafner, R. & von Reyn, C. F. Tuberculosis. N. Engl. J. Med. 368, 745-755 (2013).
2. Grange, J. M. in Tuberculosis: A Comprehensive Clinical Reference (eds Schaaf, S. & Zumla, A. I.) 44-59 (Saunders, 2009).
3. Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282, 677-686 (1999).
4. Diel, R. et al. Old ideas to innovate TB control: preventive treatment to achieve elimination. Eur. Respir. J. 8 Feb 2013 (doi:10.1183/09031936. 00205512).
5. Raviglione, M. et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 379, 1902-1913 (2012).
6. World Health Organization. Global Tuberculosis Report 2012 (WHO, 2012).
7. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis Surveillance and Monitoring in Europe (European Centre for Disease Prevention and Control, 2012).
8. Hill, A. N., Becerra, J. & Castro, K. G. Modelling tuberculosis trends in the USA. Epidemiol. Infect. 140, 1862-1872 (2012).
9. Cohen, J. Infectious disease. Approval of novel TB drug celebrated-with restraint. Science 339, 130 (2013).
10. World Health Organization. Treatment of Tuberculosis Guidelines 4th edn (WHO, 2010).
11. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC) 2nd edn (Tuberculosis Coalition for Technical Assistance, 2009)
12. Johnson, J. L. et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am. J. Respir. Crit. Care Med. 180, 558-563 (2009).
13. Lienhardt, C. et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the study C randomized controlled trial. JAMA 305, 1415-1423 (2011).
14. Dooley, K. E. et al. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clin. Infect. Dis. 55, 572-581 (2012).
15. Falzon, D. et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J. 38, 516-528 (2011).
16. Lawn, S. D. & Zumla, A. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect. Dis. 13, 349-361 (2013).
17. Weyer, K. et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert®MTB/RIF. Eur. Respir. J. 22 Nov 2012 (doi:10.1183/09031936.00157212).
18. Gandhi, N. R. et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575-1580 (2006).
19. Dheda, K. et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 375, 1798-1807 (2010).
20. Jacobson, K. R., Tierney, D. B., Jeon, C. Y., Mitnick, C. D. & Murray, M. B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis. 51, 6-14 (2010).
21. Migliori, G. B. et al. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur. Respir. J. 11 Oct 2012 (doi:10.1183/09031936.00136312).
22. Udwadia, Z. F., Amale, R. A., Ajbani, K. K. & Rodrigues, C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 54, 579-581 (2012).
23. World Health Organization. "Totally Drug-Resistant TB": a WHO consultation on the diagnostic definition and treatment options. World Health Organization [online], http://www.who.int/tb/challenges/xdr/Report- Meeting-totallydrugresistantTB-032012.pdf (2012).
24. Cole, S. T. & Riccardi, G. New tuberculosis drugs on the horizon. Curr. Opin. Microbiol. 14, 570-576 (2011).
25. Koul, A., Arnoult, E., Lounis, N., Guillemont, J. & Andries, K. The challenge of new drug discovery for tuberculosis. Nature 469, 483-490 (2011)
26. Global-Alliance for TB Drug Development. Tuberculosis. Scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb.) 81, (Suppl. 1), 1-52 (2001).
27. Barry, C. E. et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Rev. Microbiol. 7, 845-855 (2009).
28. Jindani, A., Doré, C. J. & Mitchison, D. A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167, 1348-1354 (2003).
29. Donald, P. R. & Diacon, A. H. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb.) 88, (Suppl. 1), 75-83 (2008).
30. Nuermberger, E. L. et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169, 421-426 (2004).
31. Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J. & Wang, X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 375, 2100-2109 (2010).
32. Rosenthal, I. M. et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4, e344 (2007).
33. Sterling, T. R. et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. 365, 2155-2166 (2011).
34. Diacon, A. H. et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51, 2994-2996 (2007).
35. van Ingen, J. et al. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin. Infect. Dis. 52, e194-e199 (2011).
36. Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227 (2005).
37. Dey, T. et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J. Antimicrob. Chemother. 68, 284-293 (2013).
38. Van Deun, A. et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182, 684-692 (2010).
39. Verma, R. K. et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob. Agents Chemother. 57, 1050-1052 (2013).
40. Zhang, M. et al. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob. Agents Chemother. 56, 5782-5789 (2012).
41. Ashtekar, D. R. et al. Oxazolidinone, a new class of synthetic antituberculosis agent: in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis. 14, 465-471 (1991).
42. Fortun, J. et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56, 180-185 (2005).
43. Lee, M. et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367, 1508-1518 (2012)
44. Sotgiu, G. et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J. 40, 1430-1442 (2012).
45. Wallis, R. S. et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob. Agents Chemother. 55, 567-574 (2010).
46. Wallis, R. S. et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202, 745-751 (2010).
47. Wallis, R. S. et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS ONE 7, e30479 (2012).
48. Reele, S. et al. A 14-day multiple ascending dose study: AZD5847 is well tolerated at predicted exposure for treatment of tuberculosis (TB) (Abstract A1-1735). 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy [online], http://www.abstractsonline.com/plan/ViewAbstract.asp x?mID=2789&sKey=0b498641-f10a-4936-b80c-d 274ffe4b143&cKey=2271e63a- 2cdc-4956-b7b0-6f7dc642b346&mKey=%7B0C918954-D607-46A7-8 073-44F4B537A439%7D (2011).
49. Hugonnet, J. E. et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323, 1215-1218 (2009).
50. Kumar, P. et al. Meropenem inhibits D, D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol. Microbiol. 86, 367-381 (2012).
51. Dauby, N., Muylle, I., Mouchet, F., Sergysels, R. & Payen, M. C. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr. Infect. Dis. J. 30, 812-813 (2011).
52. De Lorenzo, S. et al. Efficacy and safety of meropenem/clavunate added to linezolid containing regimens in the treatment of M/XDR-TB. Eur. Respir. J. 20 Sept 2012 (doi:10.1183/09031936.00124312).
53. Koul, A. et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chem. Biol. 3, 323-324 (2007).
54. Haagsma, A. C. et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother. 53, 1290-1292 (2009).
55. Huitric, E. et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother. 54, 1022-1028 (2009).
56. 0 ATP synthase and a novel model for mechanism of action of the TB drug TMC207. Antimicrob. Agents Chemother. 57, 168-176 (2013).
57. Koul, A. et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273-25280 (2008).
58. Rao, S. P., Alonso, S., Rand, L., Dick, T. & Pethe, K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 105, 11945-11950 (2008).
59. Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397-2405 (2009).
60. Veziris, N. et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 179, 75-79 (2009).
61. Lounis, N. et al. Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207. J. Clin. Microbiol. 46, 2212-2215 (2008).
62. Lin, P. L. et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc. Natl Acad. Sci. USA 109, 14188-14193 (2012).
63. Stover, C. K. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962-966 (2000).
64. Matsumoto, M. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3, e466 (2006).
65. Manjunatha, U. H. et al. Identification of a nitroimidazo-oxazine- specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 431-436 (2006).
66. Singh, R. et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322, 1392-1395 (2008).
67. Manjunatha, U. H. et al. Mycobacterium leprae is naturally resistant to PA-824. Antimicrob. Agents Chemother. 50, 3350-3354 (2006).
68. Hurdle, J. G. et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J. Antimicrob. Chemother. 62, 1037-1045 (2008).
69. Manjunatha, U., Boshoff, H. I. & Barry, C. E. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun. Integr. Biol. 2, 215-218 (2009).
70. Diacon, A. et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824; Antimicrob. Agents Chemother. 56, 3027-3031 (2012).
71. Diacon, A. H. et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380, 986-993 (2012)
72. Diacon, A. H. et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis. 15, 949-954 (2011).
73. Gler, M. T. et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 366, 2151-2160 (2012).
74. Skripconoka, V. et al. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur. Respir. J. 27 Sept 2012 (doi:10.1183/09031936.00125812).
75. Lee, R. E. et al. Combinatorial lead optimization of [1, 2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 5, 172-187 (2003).
76. Tahlan, K. et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 1797-1809 (2012)
77. Reddy, V. M., Einck, L., Andries, K. & Nacy, C. A. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob. Agents Chemother. 54, 2840-2846 (2010).
78. Grzegorzewicz, A. E. et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nature Chem. Biol. 8, 334-341 (2012).
79. La Rosa, V. et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 56, 324-331 (2012).
80. Stanley, S. A. et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7, 1377-1384 (2012).
81. Makarov, V. et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801-804 (2009).
82. Pasca, M. R. et al. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob. Agents Chemother. 54, 1616-1618 (2010).
83. Lechartier, B., Hartkoorn, R. C. & Cole, S. T. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 5790-5793 (2012).
84. Neres, J. et al. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci. Transl. Med. 4, 150ra121 (2012).
85. Trefzer, C. et al. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2′-epimerase DprE1 of Mycobacterium tuberculosis. J. Am. Chem. Soc. 132, 13663-13665 (2010).
86. Trefzer, C. et al. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2′-oxidase DprE1. J. Am. Chem. Soc. 134, 912-915 (2012).
87. Christophe, T. et al. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5, e1000645 (2009).
88. Magnet, S. et al. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinb.) 90, 354-360 (2010).
89. Nunn, A. J., Phillips, P. P. & Mitchison, D. A. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int. J. Tuberc. Lung Dis. 14, 241-242 (2010).
90. Merle, C. S. et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the gatifloxacin for TB (OFLOTUB) project. Trials 13, 61 (2012).
91. Phillips, P. P. et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J. Infect. Dis. 205, (Suppl. 2), 250-257 (2012).
92. Wallis, R. et al. Tuberculosis biomarkers discovery: developments, needs and challenges. Lancet Infect. Dis. 13, 362-372 (2013).
93. Horne, D. J. et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect. Dis. 10, 387-394 (2010).
94. Walzl, G., Ronacher, K., Hanekom, W., Scriba, T. J. & Zumla, A. Immunological biomarkers of tuberculosis. Nature Rev. Immunol. 11, 343-354 (2011).
95. McNerney, R. et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J. Infect. Dis. 205 (Suppl. 2), 147-158 (2012).
96. Nahid, P. et al. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am. J. Respir. Crit. Care Med. 184, 972-979 (2011).
97. Skrahina, A. et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur. Respir. J. 39, 1425-1431 (2012).
98. Abubakar, I. et al. Drug resistant tuberculosis: time for visionary political leadership. Lancet Infect. Dis. 24 Mar 2013 (doi:10.1016/S1473- 3099(13) 70030-6).
99. Schatz, A., Bugie, E. & Waksman, S. A. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 55, 66-69 (1944).
100. Wassersug, J. D. Pulmonary tuberculosis. N. Engl. J. Med. 235, 220-229 (1946).
101. Marshall, G. Streptomycin in the treatment of pulmonary tuberculosis. A Medical Research Council investigation. BMJ 1, 382-386 (1949).
102. American Thoracic Society. Treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167, 603-662 (2003).
103. Gengiah, T. N., Gray, A. L., Naidoo, K. & Karim, Q. A. Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin. Drug Saf. 10, 559-574 (2011).
104. Havlir, D. V. et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med. 365, 1482-1491 (2011).
105. Blanc, F. X. et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med. 365, 1471-1481 (2011).
106. De Cock, K. M. & El-Sadr, W. M. When to start ART in Africa-an urgent research priority. N. Engl. J. Med. 368, 886-889 (2013).
107. Subbian, S. et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog. 7, e1002262 (2011).
108. Tobin, D. M. et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148, 434-446 (2012).
109. Skerry, C., Harper, J., Klunk, M., Bishai, W. R. & Jain, S. K. Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS ONE 7, e39680 (2012).
110. Napier, R. J. et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 10, 475-485 (2012).
111. Ivanyi, I. & Zumla, A. Non-steroidal anti-inflammatory drugs for adjunctive tuberculosis treatment. J. Infect. Dis. 5 Apr 2013 (doi:10.1093/infdis/jit153).
112. Amaral, L., Martins, M. & Viveiros, M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother. 59, 1237-1246 (2007).
113. Adams, K. N. et al. Drug tolerance in replicating mycobacteria mediate macrophage-induced efflux mechanism. Cell 145, 39-53 (2011).
114. Lim, L. E. et al. Anthelmintic avermectins kill M. tuberculosis, including multidrug-resistant clinical strains. Antimicrob. Agents Chemother. 57, 1040-1046 (2013).
115. Maiga, M. et al. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS ONE 7, e30749 (2012).
116. Uhlin, M., Andersson, J., Zumla, A. & Maeurer, M. Adjunct immunotherapies for tuberculosis. J. Infect. Dis. 205 (Suppl. 2), 325-334 (2012).
117. Bruns, H. et al. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J. Immunol. 189, 4069-4078 (2012).
118. Kuijl, C. et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature. 450, 725-730 (2007).
119. Boshoff, H. I. & Barry, C. E. 3rd. Tuberculosis-metabolism and respiration in the absence of growth. Nature Rev. Microbiol. 3, 70-80 (2005).
120. Pym, A. S. & Cole, S. T. in Bacterial Resistance to Antimicrobials 2nd Edn (eds Wax, R. G., Lewis, K., Salyers, A. A. & Taber, H.) 313-342 (CRC, 2008).
121. Shi, W. et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333, 1630-1632 (2011).
122. Chakraborty, S., Gruber, T., Barry, C. E. 3rd, Boshoff, H. I. & Rhee, K. Y. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 339, 88-91 (2013).
123. Sirgel, F. A. et al. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 67, 1088-1093 (2012).
124. Sirgel, F. A. et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb. Drug Resist. 18, 193-197 (2012).
125. Salian, S. et al. Structure-activity relationships among the kanamycin aminoglycosides: role of ring I hydroxyl and amino groups. Antimicrob. Agents Chemother. 56 6104-6108 (2012)
126. Global Alliance for TB Drug Development. Cycloserine. Tuberculosis (Edinb.) 88, 100-101 (2008).
127. Bruning, J. B., Murillo, A. C., Chacon, O., Barletta, R. G. & Sacchettini, J. C. Structure of the Mycobacterium tuberculosis D-alanine:D-alanine ligase, a target of the antituberculosis drug D-cycloserine. Antimicrob. Agents Chemother. 55, 291-301 (2010).
128. Benator, D. et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360, 528-534 (2002).
129. Steingart, K. R., et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int. J. Tuber. Lung Dis. 15, 305-316 (2011).
130. Batt, S. M., et al. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl Acad. Sci. USA 109, 11354-11359 (2012).